detection, classification and monitoring of prevalent cancers,
including ovarian, breast and prostate. Vermillion will have access to
exclusive commercial rights to the discoveries made through the
-- Vermillion's stockholders and board of directors approved a 1 for 10
reverse stock split of the Company's common stock. The reverse split
became effective at the close of trading on Monday, March 3, 2008.
-- The Ohio State University commercially launched Vermillion's diagnostic
test for managing patients with TTP, a hematological disease. The test
helps physicians make the correct diagnosis, initiate timely treatment,
evaluate response to therapy and predict the risk of recurrence in
patients with TTP.
-- Received issuance of U.S. Patent No. 7,297,556 for aiding diagnosis of
nephrotic syndrome, a kidney disorder marked by very high or low levels
of protein in the urine, which results in bodily swelling and high
The Company's primary goal for 2008 will be to commercialize its
diagnostic tests through collaborations with Quest Diagnostics and other
thought leaders in oncology, cardiology and hematology. Vermillion expects
to attain the following milestones:
-- Present data from three studies highlighting progress in Vermillion's
ovarian cancer diagnostic program at the Society for Gynecologic
Oncologists' (SGO) 2008 Annual Meeting on Women's Cancer held
March 9-12 in Tampa, Florida.
-- Report top-line data from the ovarian tumor triage clinical trial later
this quarter and submit to the U.S. Food and Drug Administration (FDA)
for clearance as an in vitro diagnostic test in the first half of 2008.
-- Work with Quest Diagnostics to integrate Vermillion's PAD proteomic
biomarkers as a laboratory
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved